A 9-Day Losing Streak Has Aehr Test Systems Stock Down 45%
A nine-day slide has erased billions in value, but the stock’s story is more than just this recent move.
Aehr Test Systems (AEHR) stock has now moved lower for 9 consecutive trading days, a cumulative loss of 45%. That streak has erased about $2.1 billion from the company’s market value, which now stands at about $2.6 billion.
For anyone holding the stock, this kind of persistent selling can test conviction, forcing a fresh look at the relationship between the company’s performance and its price.
AEHR Versus The S&P 500, Streak And Beyond
Here is how AEHR stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | AEHR | S&P 500 |
|---|---|---|
| 1D | -10.7% | -0.2% |
| 9D (Current Streak) | -44.5% | -0.4% |
| 1M (21D) | 5.1% | 3.7% |
| 3M (63D) | -12.5% | 1.7% |
| YTD 2026 | 300.2% | 12.7% |
| 2025 | 21.4% | 16.4% |
| 2024 | -37.3% | 23.3% |
| 2023 | 32.0% | 24.2% |
Does the business performance justify the selling?
The move appears to be specific to the company, not the broader market. Over the same 9 trading days, the S&P 500 returned -0.4%. The pressure on the stock comes against a backdrop of real strain in the underlying business fundamentals. Revenue over the last twelve months declined 15.2%, compared to an S&P 500 median revenue growth of 8.3%. The company’s 3-year average annual revenue growth is -8.1%.
Profitability is also a challenge. Aehr Test Systems’ operating margin over the last twelve months is -28.3%, while the S&P 500 median is 18.5%. The company has negative trailing earnings and does not have a meaningful price-to-earnings multiple. Still, this recent slide follows a period of very strong performance; the stock has returned +232.6% over the trailing twelve months.
So what does a streak actually tell you?
A streak is not a signal to buy or sell. It is simply information. It tells you that a stock has the market’s focused attention, and that momentum, in this case downward, has been persistent. The disciplined move is not to react to the streak itself, but to use it as a prompt to check your thesis.
The most durable investment decisions come from comparing the price of a stock to the health of its business. The numbers here provide a starting point for that work.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
Prefer the theme to this single name? Our ETF Scorecard shows how the technology funds stack up. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.